Funder
Fresenius Medical Care Renal Therapies Group
Abbott
AbbVie
Alexion
Amgen
ASN
Astra-Zeneca
AVEO
Chugai
DaVita
Fresenius
Genentech
Haymarket Media
Hofstra Medical School
IFKF
ISH
International Society of Renal Nutrition & Metabolism
JSDT
Hospira
Kabi
Keryx
Novartis
OPKO
NIH
National Institutes of Health
NKF
Pfizer
Relypsa
Resverlogix
Sandoz
Sanofi
Shire
Vifor
UpToDate
ZS-Pharma
Subject
Nephrology,Nutrition and Dietetics,Medicine (miscellaneous)
Reference32 articles.
1. Patient-reported factors associated with poor phosphorus control in a maintenance hemodialysis population;Joson;J Ren Nutr,2016
2. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphatemia: a randomized, open-label, multicentre, 12-week phase III study;Koiwa;Nephrology (Carlton),2017
3. Hyperphosphatemia management in patients with chronic kidney disease;Shaman;Saudi Pharm J,2016
4. Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: findings from the DOPPS;Fissell;Hemodial Int,2016
5. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles;Locatelli;Expert Opin Drug Saf,2014
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献